Merry Christmas, Happy Hanukkah, and Season’s Greetings to all our Shareholders.

Dear Shareholders

The other morning, I came across an article published on RealClearScience about the Christmas spider. This is a tale from Eastern Europe about a spider who spins a beautiful web in a family’s home on Christmas Eve. The glistening web then transforms to silver, a joy and blessing to the family, the value of which elevates them from poverty to prosperity[1].

I was vaguely aware of this story and had been gifted a small ornamental spider years ago, which is always hanging in my home. Reading that story this morning makes me think about the immediate future of Kraig Biocraft Laboratories and the blessings I believe we are poised to gift to the world over this coming year.

2025 was a year of growth and evolution for Kraig Labs. Together, we’ve achieved significant milestones that have strengthened our Company and positioned us for greater success in 2026.

This year kicked off with a series of operational and scientific breakthroughs that I believe will underpin a new year of growth and advancement across the core pillars of our business, spider silk production, end-market commercialization, and research and development of advanced materials.

Our R&D achievements in 2025 expanded both the breadth and depth of our technology platform. Early in the year, we announced the successful development of a recombinant Darwin Bark Spider silk, demonstrating our ability to engineer and express increasingly complex silk proteins with unique performance characteristics. We quickly followed this up with the creation of a Caddis Fly silk, opening the door to entirely new classes of biomaterials with potential for adhesion and underwater performance.

Our introduction of an advanced gene-splicing technology spurred the rapid pace of these developments. This work ultimately led Kraig Labs to a scientific breakthrough that set the world record, doubling the largest known gene insert in silkworm (opening the door for more advanced materials). Collectively, these advancements strengthen the technological foundation upon which all future new materials at Kraig Labs will be built.

2025 marked a stressful, yet pivotal, year in the evolution of our production operations. This year, we set a production record for advanced spider silk reeling utilizing automated reeling equipment – a key breakthrough needed to achieve multi-ton production. However, we fell short of our ultimate total production target.

In late 2025, we released the new BAM-1 ALPHA hybrid (“ALPHA”) that moved us fully into a true production diapausing hybrid. A huge advancement in production that we had been working on for years. 

The ALPHA hybrid produces the same recombinant spider silk as the original BAM-1.  The difference lies entirely in the background genetics that affect almost every other part of the silkworm, except the transgenic silk sequences.  In other words, ALPHA contains no altered transgenic traits from the original BAM-1.  What differentiates ALPHA from the original BAM-1 is that the parental strains (which both carry the original trans genes) are from a different lineage and are as distinct from the originals as a Golden Retriever is from a Rottweiler. 

The improved background genetics results in a critical 22% boost in silk yield compared to the parental strains. That 22% is very significant for increased production and commercialization. ALPHA also boasts improved reeling efficiency on automated machines, all while maintaining the same strength and materials performance, a game-changer for us in 2026.

To support the increased output of the ALPHA hybrids, we added parallel manufacturing facilities, allowing multiple production streams to operate simultaneously. The operational flexibility, capacity, and resilience of this model were key to our fourth-quarter production breakthrough. We’ve produced more than one million ALPHA eggs, which are ready for deployment to make finished spider silk yarn. These achievements reflect years of selective breeding and targeted design efforts that are now translating into meaningful scale and robustness.

Our accomplishments this year were not made alone. In 2025, we were granted operating licenses by two Southeast Asian countries, providing production security and diversification as we continue to leverage the capabilities of our new production spider silk transgenics. We also signed a strategic multi-year collaboration agreement with a key government agency in Southeast Asia, supporting our production growth and providing key resources, facilities, and land. This agreement was the result of several years of groundwork by our team to secure critical support and resources for our operations and the expansion of spider silk production. As we enter 2026, these collaborations are expanding with the granting of lease rights on additional mulberry gardens to supply our growing production capacity.

The addition of parallel manufacturing facilities and our strategic multi-country licensing expansion further diversified our production base, reduced operational risk, and positioned the Company for sustained, scalable growth across Southeast Asia.

Perhaps most exciting, 2025 marked the beginning of Kraig Labs’ transition from development to commercialization and spider silk sales. This year, we engaged with market leaders in the performance sportswear, sports equipment, and luxury fashion segments. The excitement from these segments to explore applications for our spider silk in their product offerings can now be met with near-term product capacity. In November, we secured our first commercial trial order, an important validation of both our technology and our readiness to serve customers in real-world applications. We believe this is just the first of many orders and opportunities for spider silk.

As we look toward 2026, we do so with growing excitement. The accomplishments of 2025, many of which are not yet reflected in our metrics, have built a rock-solid foundation for the years ahead. Our science is stronger, our production is larger and more resilient, our footprint is expanding, and early-stage commercialization is now underway.

On behalf of the entire Kraig Biocraft Laboratories team, we thank you for your patience, belief, and continued support. We look forward to sharing the next chapter of this journey with you.

From all of us at Kraig Biocraft Laboratories, we wish you a peaceful holiday season and a healthy, prosperous New Year. Warmest holiday greetings and sincere appreciation to you and yours.

With gratitude, resolve, and with the warmest wishes for a Merry Merry Christmas and Happy Hanukkah

Kim K. Thompson
Founder & Chief Executive Officer
On behalf of the entire Kraig Labs family

[1] https://www.zmescience.com/feature-post/culture/culture-society/christmas-spiders/

Breakthrough hybrid line continues to demonstrate superior resilience and scalability as the Company advances major production expansion initiatives

ANN ARBOR, Mich., December 15, 2025 – Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company” or “Kraig Labs”), a world leader in spider silk technology*, today announced the successful completion of its most recent production cycle, yielding more than one million BAM-1 Alpha hybrid eggs. These eggs are now staged for release over the next quarter and will serve as the next wave of recombinant spider silk production.

This milestone marks another decisive validation of the Company’s strategic transition to this more advanced spider silk line. The BAM-1 Alpha line has delivered greater uniformity and significantly greater resiliency throughout every phase of the production process. These gains directly translate into improved throughput, consistency, and reliability for the Company’s expanding spider silk manufacturing platform.

“The success of BAM-1 Alpha is reshaping our production capabilities,” said Kim Thompson, Founder and CEO of Kraig Labs. “These results reaffirm the power of this hybrid line, and to surpass the one-million-egg mark so quickly is further evidence that we are scaling efficiently, effectively, and in direct alignment with our commercial objectives.”

The rising production capacity enabled by BAM-1 Alpha is also fueling the Company’s accelerated expansion initiatives currently underway in Southeast Asia.

“With each new batch, we are strengthening the backbone of our commercial rollout,” Thompson continued. “The reliability and robustness of BAM-1 Alpha allow us to move forward quickly with confidence as we expand production.”

The Company has developed an aggressive production schedule for the next 6 months based on these exciting results and is already putting that plan into action.

For the latest updates on Kraig Labs and its pioneering spider silk technologies, visit www.kraiglabs.com.

For details about other recent Kraig Labs advancements, please watch the Company’s investor conference at www.kraiglabs.com/videos or on the Company’s YouTube Channel https://www.youtube.com/@kraigbiocraftlaboratories2270. 

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news   

* For a description of our historical leadership in this technology, please follow this link  https://www.kraiglabs.com/world-leader/

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk-based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, Inc.

(720) 288-8495

ir@KraigLabs.com

ANN ARBOR, Mich., December 8, 2025 – Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company” or “Kraig Labs”), a world leader in spider silk technology*, today announced that it has been granted usage rights to a significant block of government-owned mulberry gardens located near its spider silk production operations in Southeast Asia.

These land-use rights, granted to Kraig Labs by a key government agency as part of the Company’s collaborative relationship, will play a central role in Kraig Labs’ ongoing production expansion. The Company has agreed to pay a nominal rent for the use of the mulberry gardens. These mulberry gardens will provide the essential feedstock required to support the scaled-up of recombinant spider silk production. This added capacity will directly support the manufacturing of high-performance spider silk yarns targeted at performance textiles, technical apparel, and luxury fashion markets.

The newly secured acreage will provide a reliable and strategically positioned source of high-quality mulberry leaf, an essential input for maintaining production throughput and improved logistics. This alignment between land access, production capacity, and downstream processing is a key component of Kraig Labs’ strategic expansion blueprint.

Today’s announcement follows closely on the Company’s recently announced order from a leading performance sports apparel brand. Kraig Labs is currently finalizing materials for this customer’s pilot development program, which will utilize the Company’s recombinant spider silk fibers. The addition of these mulberry gardens strengthens Kraig Labs’ ability to meet future commercial demand as it advances toward broader market deployments.

“Access to these mulberry gardens marks another critical step in building an integrated and resilient production ecosystem for our spider silk technologies,” said Kim Thompson, Founder and CEO of Kraig Biocraft Laboratories. “Securing direct access to high-quality mulberry acreage gives us greater control over our supply chain and positions us to accelerate production of our BAM-1 Alpha hybrid spider silk. This collaboration with government stakeholders reflects their confidence in the economic and technological potential of our work.”

As this land is transferred to Kraig Labs’ control, the Company will prepare the gardens for incorporation into its expanding spider silk production pipeline. Additional staffing and operational resources will be deployed as part of the integration process, supporting both near-term production increases and the Company’s strategic vision for large-scale commercialization.

For the latest updates on Kraig Labs and its pioneering spider silk technologies, visit www.kraiglabs.com.

For details about other recent Kraig Labs advancements, please watch the Company’s investor conference at www.kraiglabs.com/videos or on the Company’s YouTube Channel https://www.youtube.com/@kraigbiocraftlaboratories2270. 

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news   

* For a description of our historical leadership in this technology, please follow this link  https://www.kraiglabs.com/world-leader/

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk-based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, Inc.

(720) 288-8495

ir@KraigLabs.com

ANN ARBOR, Mich., November 25, 2025 – Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company” or “Kraig Labs”), a world leader in spider silk technology*, announces the launch of a key hiring initiative at its production operations in Southeast Asia. This expansion of the Company’s production workforce is driven by rapidly increasing throughput, an expanded operational footprint, and preparations for the opening of its newest production center, now in active development.

The Company is ramping up staffing to support what it expects to be a significant increase in production volumes over the coming quarters. These new team members will play a critical role in supporting the deployment of the Company’s advanced spider silk technologies and modernized sericulture systems across its growing network of facilities.

All incoming production staff will receive specialized training under Dr. Nirmal Kumar, one of the world’s foremost sericulture experts. Training under Dr. Kumar will prepare new hires to support operational growth at Kraig Labs’ newest production center, currently in development, increasing capacity, resilience, and commercial production of its high-performance spider silk.

“This hiring initiative reflects the incredible momentum we are building and the strength of our forward-looking production strategy,” said Kim Thompson, Founder and CEO of Kraig Labs. “As we scale up our next-generation spider silk technology and expand our production footprint, we are focused on assembling a team capable of supporting the high growth trajectory we anticipate. Bringing new staff into the fold and having them train directly with Dr. Kumar ensures that we are building the strongest possible foundation for the future of our operations.”

The Company’s expanded workforce will contribute to Kraig Labs’ increasing production capacity and its readiness to meet both near-term production targets and longer-term commercial opportunities. As construction and development of the new production center takes shape, these newly trained team members will be positioned to support the facility’s launch and help drive the Company’s next major phase of growth.

Kraig Labs expects to continue adding staff and resources as it advances its mission of delivering the world’s first cost-effective, eco-friendly, industrial-scale recombinant spider silk.

For the latest updates on Kraig Labs and its pioneering spider silk technologies, visit www.kraiglabs.com.

For details about other recent Kraig Labs advancements, please watch the Company’s investor conference at www.kraiglabs.com/videos or on the Company’s YouTube Channel https://www.youtube.com/@kraigbiocraftlaboratories2270. 

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news   

* For a description of our historical leadership in this technology, please follow this link  https://www.kraiglabs.com/world-leader/

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk-based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, Inc.

(720) 288-8495

ir@KraigLabs.com

Company to deliver spider silk yarns for elite-tier athletic application

ANN ARBOR, Mich., November 17, 2025 – Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company” or “Kraig Labs”), a world leader in spider silk technology*,  today announced that it is fulfilling an order for spider silk from a globally recognized performance sports apparel brand as part of a confidential pilot development program.

This project will incorporate the Company’s  next-generation recombinant spider silk into a cutting-edge application targeted at the highest tier of performance apparel. While specific project details remain protected, Kraig Labs can confirm that the program is designed for one of the most demanding and innovation-focused segments of the athletic market.

This customer’s market leadership, engineering sophistication, and reputation for excellence in performance apparel made them the ideal choice for this initial pilot engagement. Their market leadership and commitment to innovation is the reason Kraig Labs selected to fulfill this request from among the numerous recent inbound inquiries it received.

The Company is now processing a portion of its recombinant spider silk inventory into yarns tailored to the precise specifications provided by the customer’s development team. Delivery of these specialized materials is expected before the end of the first quarter.

As a focused pilot program, this order calls for a small, purpose-built quantity of spider silk designed explicitly for this highly specialized application. Even at this limited scale, the project provides a powerful platform for demonstrating the performance capabilities and commercial potential of the Company’s specialized spider silk technology within a premier performance environment.

“This collaboration underscores the growing recognition of our material’s potential in high-value, high-performance applications,” said Kim Thompson, Kraig Labs’ Founder and CEO. “We are excited to support this project and a customer whose commitment to innovation aligns with our own. We look forward to showcasing what our spider silk can deliver at the elite level of apparel design and performance.”

Kraig Labs will share additional updates as appropriate and consistent with the confidentiality terms of the agreement.

For the latest updates on Kraig Labs and its pioneering spider silk technologies, visit www.kraiglabs.com.

For details about other recent Kraig Labs advancements, please watch the Company’s investor conference at www.kraiglabs.com/videos or on the Company’s YouTube Channel https://www.youtube.com/@kraigbiocraftlaboratories2270. 

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news   

* For a description of our historical leadership in this technology, please follow this link  https://www.kraiglabs.com/world-leader/

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk-based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, Inc.

(720) 288-8495

ir@KraigLabs.com

ANN ARBOR, Mich., November 3, 2025 – Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company” or “Kraig Labs”), a world leader in spider silk technology*, today announced that its production operations in Vietnam remain fully secure and uninterrupted following the recent series of typhoons that have impacted parts of Southeast Asia.

Kraig Labs confirmed that its spider silk production facilities and infrastructure sustained no damage or disruption, including its mulberry feedstock supplies, from the severe weather events that caused widespread flooding in lowland regions. The Company’s strategic decision made in 2024 to relocate its operations into the protected highlands has proven to be a highly valuable investment in operational resilience and long-term stability.

“Our hearts go out to the many people and businesses across the region who have suffered loss and devastation from these storms. Kraig Labs will be contributing to the relief and recovery efforts, helping those who have been devastated by these disasters,” said Kim Thompson, Founder and CEO of Kraig Labs. “We are deeply grateful that our facilities and personnel are safe, and we remain fully operational. Our highland infrastructure investments have demonstrated their strength and strategic importance.”

Kraig Labs also confirmed that its former facility in Quang Nam province, which has since been closed, was among the areas affected by flooding. However, all Company equipment, staff, and production assets had been permanently and successfully relocated from that site in September, well ahead of the storms.

In addition to moving its infrastructure and production to the highlands, Kraig Labs has implemented a strategy of maintaining multiple, parallel production facilities. This approach not only supports scalability but also serves as an additional safeguard against potential disruptions from natural disasters or other unforeseen events. By building redundancy and flexibility into its production network, the Company continues to strengthen the foundation for long-term growth and reliability.

“With each step forward, we are building greater resilience into every part of our business,” Thompson continued. “Our investments in infrastructure, redundancy, and strategic location have put Kraig Labs in the strongest position in our history. We are confident these facilities will continue to advance our record-setting spider silk production capacity and deliver these amazing materials to consumer markets eager for innovation and disruption.”

For the latest updates on Kraig Labs and its pioneering spider silk technologies, visit www.kraiglabs.com.

For details about other recent Kraig Labs advancements, please watch the Company’s investor conference at www.kraiglabs.com/videos or on the Company’s YouTube Channel https://www.youtube.com/@kraigbiocraftlaboratories2270. 

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news   

* For a description of our historical leadership in this technology, please follow this link  https://www.kraiglabs.com/world-leader/

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk-based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, Inc.

(720) 288-8495

ir@KraigLabs.com

ANN ARBOR, Mich., October 27, 2025 – Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company” or “Kraig Labs”), a world leader in spider silk technology*, today announced the promotion of Dr. Xiaoli Zhang to the position of Chief Scientist. This promotion follows a series of groundbreaking scientific achievements under Dr. Zhang’s leadership that are laying the foundation for the next generation of spider silk-based super materials.

Dr. Zhang joined Kraig Labs in October 2024 and was challenged with accelerating the Company’s research program and unlocking new scientific frontiers. Tasked with ambitious and transformative objectives, she not only met but exceeded every milestone in record time, positioning Kraig Labs at the forefront of breakthrough discoveries in advanced fibers and bioengineered materials.

“These achievements are nothing short of revolutionary,” said Kim Thompson, founder and CEO of Kraig Labs. “When Dr. Zhang came on board, we asked her to take on challenges that many believed were impossible. In less than a year, she has led our team to breakthroughs that open the door to entirely new categories of super materials. Her promotion to Chief Scientist reflects both the incredible work she has already done and the even more extraordinary advancements we expect under her continued leadership.”

The innovations driven by Dr. Zhang’s research are now forming the blueprint for a new era of material science, pushing the boundaries of what spider silk can achieve. These advancements promise to redefine performance materials and open new opportunities in higher-margin end markets.

“I am deeply honored by this recognition,” said Dr. Zhang. “The past year has shown us what’s possible when science, vision, and determination come together. What we’ve achieved is just the starting point, we are now poised to pioneer materials that will set entirely new standards for strength, flexibility, and performance. The future for spider silk is brighter than ever.”

With Dr. Zhang leading its research initiatives, Kraig Labs remains firmly positioned as a global leader in spider silk innovation, charting a bold course toward the super materials of tomorrow.

Today’s announcement pairs with the breakthroughs in spider silk production at its operations centers in Southeast Asia, further reinforcing the Company’s leading position in the commercialization of sustainable and cost-effective spider silk.

For the latest updates on Kraig Labs and its pioneering spider silk technologies, visit www.kraiglabs.com.

For details about other recent Kraig Labs advancements, please watch the Company’s investor conference at www.kraiglabs.com/videos or on the Company’s YouTube Channel https://www.youtube.com/@kraigbiocraftlaboratories2270. 

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news   

* For a description of our historical leadership in this technology, please follow this link  https://www.kraiglabs.com/world-leader/

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk-based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, Inc.

(720) 288-8495

ir@KraigLabs.com

ANN ARBOR, Mich., October 20, 2025 – Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company”, “Kraig” or “Kraig Labs”), a world leader in spider silk technology*, is proud to announce the kickoff of its sixth spider silk production cycle for 2025, featuring the first large-scale deployment of its BAM-1 Alpha, the newest and most advanced evolution of the Company’s recombinant spider silk technology.

Following a year of record technical progress and expanded production, Kraig Labs is entering this next cycle with renewed momentum and enhanced output capability. The BAM-1 Alpha hybrid builds directly upon the Company’s 2024 breakthroughs, delivering stronger performance and higher silk yields while remaining fully aligned with Kraig’s established aggressive production schedule.

“This is an exhilarating moment for Kraig Labs,” said Kim Thompson, Founder and CEO of Kraig Labs. “BAM-1 Alpha represents the next step in the evolution of our spider silk technology. It’s the result of years of focused innovation and the foundation of our future growth.”

This latest production run continues the scale-up of BAM-1 Alpha parental lines, utilizing the same successful framework introduced this summer with the integration of diapause egg management into Kraig Labs’ rearing operations. This integration enables greater production efficiency, smoother logistics, and sustained throughput across multiple production cycles.

As evident by the rapid integration of BAM-1 Alpha into this production cycle launch, this transition to a more advanced hybrid requires no changes to its production schedule or rearing infrastructure, it simply delivers more spider silk per production cycle. The consistency of the Company’s process, combined with the continued evolution of its hybrids, underscores Kraig’s growing leadership in sustainable, high-performance bioengineered super fibers.

“As we move deeper into this next evolution of spider silk, we’re seeing real, measurable results,” Thompson added. “Our team has built a production engine that’s not only scalable, but continuously improving. BAM-1 Alpha is a major leap forward, and it positions us perfectly for the commercial expansion and capacity to meet the growing demand for spider silk.”

For the latest updates on Kraig Labs and its pioneering spider silk technologies, visit www.kraiglabs.com.

For details about other recent Kraig Labs advancements, please watch the Company’s investor conference at www.kraiglabs.com/videos or on the Company’s YouTube Channel https://www.youtube.com/@kraigbiocraftlaboratories2270. 

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news   

* For a description of our historical leadership in this technology, please follow this link  https://www.kraiglabs.com/world-leader/

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk-based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, Inc.

(720) 288-8495

ir@KraigLabs.com

ANN ARBOR, Mich., October 13, 2025 – Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company” or “Kraig Labs”), a world leader in spider silk technology*, is proud to announce the Company has succeeded in significantly increasing the production throughput of its recombinant spider silk production platform.   

This increase is the successful result of the Company’s continuous work in the selective breeding of parental strains for its production hybrid silkworms, which is the basis of its recombinant spider silk production system. Kraig’s first successful hybrid, designated the BAM-1, demonstrated hybrid vigor, which increased both cocoon shell weight (a critical measure of silk output) and robustness. That hybrid was created by mating two genetically divergent parental strains. The fielding of the BAM-1 was a major improvement in spider silk production technology. 

Over the past two years, the Company has been using selective breeding to create more advanced parental strains with the goal of increasing hybrid vigor to further increase shell weight. One of these new advanced strains was specifically designed as a replacement for one of the original BAM-1 parental strains.

By mating the strongest of the BAM-1 parental strains with the new advanced strain, the Company has demonstrated measurable hybrid vigor (as measured by cocoon shell weight) of 22%, an increase in hybrid vigor of more than 245% compared to the BAM-1. The new advanced hybrid has been designated as BAM-1 Alpha and will be the Company’s production workhorse moving forward.

“Our small team of researchers continues to outperform our competitors in spider silk R&D and commercial development. The creation of our new BAM-1 Alpha hybrid is the product of our focused vision for large-scale commercialization of spider silk and the dedication of our geneticists to that vision,” said Kim Thompson, Founder and CEO of Kraig Labs. “Frankly, the 250% increase in hybrid vigor over the original BAM-1 has significantly exceeded our expectations and design parameters. The BAM-1 Alpha is producing larger cocoons and more silk, resulting in increased throughput and lower production cost. Though we do not have hard data yet on increases in robustness other than cocoon size and shell weight, our expectation is that general robustness will follow this same pattern.”

Kraig Labs utilizes its proprietary genetically enhanced silkworm technology platform to produce recombinant spider silk. These silkworms spin recombinant spider silk fibers naturally within their cocoons, combining the scalability of traditional sericulture with the superior performance of spider silk proteins.

With BAM-1 Alpha now moving into commercial deployment, Kraig Labs will leverage its multi-facility production infrastructure to integrate this enhanced production hybrid into ongoing manufacturing. This advancement supports the Company’s vision of delivering high-performance spider silk fibers for applications spanning performance textiles, defense, medical, and industrial markets.

This latest development underscores Kraig Labs’ commitment to continuous innovation and its leadership in developing scalable bioengineered materials inspired by nature’s toughest fibers.

For the latest updates on Kraig Labs and its pioneering spider silk technologies, visit www.kraiglabs.com.

For details about other recent Kraig Labs advancements, please watch the Company’s investor conference at www.kraiglabs.com/videos or on the Company’s YouTube Channel https://www.youtube.com/@kraigbiocraftlaboratories2270. 

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news   

* For a description of our historical leadership in this technology, please follow this link  https://www.kraiglabs.com/world-leader/

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk-based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, Inc.

(720) 288-8495

ir@KraigLabs.com

ANN ARBOR, Mich., October 6, 2025 – Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company” or “Kraig Labs”), a world leader in spider silk technology*, today announced that it is preparing to add a third production facility as part of its plans for rapid expansion of recombinant spider silk production.

Over the past 18 months, Kraig Labs has significantly advanced its production model, opening two rearing centers for recombinant spider silk production. The Company is now opening a third center to expand its capacity further.

The Company reports that it is now well underway in identifying a site for this new facility and anticipates finalizing a location within the next 60 days.

This new facility, like the Company’s existing operations, will be established in one of the world’s leading silk production regions. By situating operations within established silk-growing areas, the Company is able to leverage an experienced workforce, robust infrastructure, and a long-standing tradition of excellence in sericulture.

Kraig Labs’ multi-facility strategy is designed to support continuous production. By building redundancies directly into the production chain, the Company has created a stronger and more resilient foundation to meet the current demand and growing market for its recombinant spider silk materials.

“We are looking now for the site of an additional rearing center in order to further expand our production capacity,” said Kim Thompson, Kraig Labs’ founder and CEO. “We expect to lock in the site within the next 60 days. The goal is to further increase our capacity while building in resilience.”

The addition of this new rearing center represents another milestone in Kraig Labs’  expansion of its production capacity and its plans to bring the performance and sustainability benefits of recombinant spider silk to global markets.

For the latest updates on Kraig Labs and its pioneering spider silk technologies, visit www.kraiglabs.com.

For details about other recent Kraig Labs advancements, please watch the Company’s investor conference at www.kraiglabs.com/videos or on the Company’s YouTube Channel https://www.youtube.com/@kraigbiocraftlaboratories2270. 

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news   

* For a description of our historical leadership in this technology, please follow this link  https://www.kraiglabs.com/world-leader/

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk-based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, Inc.

(720) 288-8495

ir@KraigLabs.com